MedTrace Logo

Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study

NCT05927558 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2023-12-29

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the anti-lymphoma activity of glofitamab, administered according to the Compassionate Use Program, in relapsed/refractory B-NHL patients. The main question it aims to answer is the rate of patients in complete response.

Conditions

  • B-cell Non Hodgkin Lymphoma
  • Relapse
  • Refractory Lymphoma

Sponsors & Collaborators

  • Gruppo Italiano Malattie EMatologiche dell'Adulto

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-22
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05927558 on ClinicalTrials.gov